| Pembrolizumab cutaneous adverse events and their association with disease progression M Sanlorenzo, I Vujic, A Daud, A Algazi, M Gubens, SA Luna, K Lin, ... JAMA dermatology 151 (11), 1206-1212, 2015 | 444 | 2015 |
| Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium P Quaglino, M Maule, HM Prince, P Porcu, S Horwitz, M Duvic, R Talpur, ... Annals of Oncology 28 (10), 2517-2525, 2017 | 140 | 2017 |
| The risk of melanoma in airline pilots and cabin crew: a meta-analysis M Sanlorenzo, MR Wehner, E Linos, J Kornak, W Kainz, C Posch, I Vujic, ... JAMA dermatology 151 (1), 51-58, 2015 | 135 | 2015 |
| Melanoma immunotherapy M Sanlorenzo, I Vujic, C Posch, A Dajee, A Yen, S Kim, M Ashworth, ... Cancer biology & therapy 15 (6), 665-674, 2014 | 104 | 2014 |
| Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma M Sanlorenzo, A Choudhry, I Vujic, C Posch, K Chong, K Johnston, ... Journal of the American Academy of Dermatology 71 (6), 1102-1109. e1, 2014 | 94 | 2014 |
| Association of histologic regression in primary melanoma with sentinel lymph node status: a systematic review and meta-analysis S Ribero, MR Gualano, S Osella-Abate, G Scaioli, F Bert, M Sanlorenzo, ... JAMA dermatology 151 (12), 1301-1307, 2015 | 89 | 2015 |
| Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role? S Ribero, S Osella-Abate, M Sanlorenzo, E Balagna, R Senetta, MT Fierro, ... Annals of Surgical Oncology 22, 1967-1973, 2015 | 87 | 2015 |
| Favourable prognostic role of regression of primary melanoma in AJCC stage I–II patients S Ribero, S Osella‐Abate, M Sanlorenzo, P Savoia, C Astrua, G Cavaliere, ... British Journal of Dermatology 169 (6), 1240-1245, 2013 | 84 | 2013 |
| DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics A Latorre, C Posch, Y Garcimartín, A Celli, M Sanlorenzo, I Vujic, J Ma, ... Nanoscale 6 (13), 7436-7442, 2014 | 80 | 2014 |
| Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer I Vujic, M Sanlorenzo, C Posch, R Esteve-Puig, AJ Yen, A Kwong, ... Oncotarget 6 (2), 969, 2015 | 75 | 2015 |
| Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature I Vujic, A Shroff, M Grzelka, C Posch, B Monshi, M Sanlorenzo, ... Journal of the European Academy of Dermatology and Venereology 29 (3), 595-598, 2015 | 71 | 2015 |
| Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years S Osella‐Abate, S Ribero, M Sanlorenzo, MM Maule, L Richiardi, ... International journal of cancer 136 (10), 2453-2457, 2015 | 64 | 2015 |
| Apremilast in psoriasis–a prospective real‐world study I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi, K Rappersberger, ... Journal of the European Academy of Dermatology and Venereology 32 (2), 254-259, 2018 | 63 | 2018 |
| Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma C Posch, BD Cholewa, I Vujic, M Sanlorenzo, J Ma, ST Kim, S Kleffel, ... Journal of Investigative Dermatology 135 (10), 2475-2483, 2015 | 63 | 2015 |
| The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis P Dapavo, I Vujic, MT Fierro, P Quaglino, M Sanlorenzo Journal of the American Academy of Dermatology 75 (4), 736-739, 2016 | 49 | 2016 |
| The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes M Sanlorenzo, I Vujic, C Posch, JE Cleaver, P Quaglino, S Ortiz-Urda JAMA dermatology 151 (4), 450-452, 2015 | 46 | 2015 |
| Cytokine-induced killer cells kill chemo-surviving melanoma cancer stem cells L Gammaitoni, L Giraudo, M Macagno, V Leuci, G Mesiano, R Rotolo, ... Clinical Cancer Research 23 (9), 2277-2288, 2017 | 40 | 2017 |
| Phenotypical markers, molecular mutations, and immune microenvironment as targets for new treatments in patients with mycosis fungoides and/or Sézary syndrome P Quaglino, P Fava, A Pileri, V Grandi, M Sanlorenzo, V Panasiti, ... Journal of Investigative Dermatology 141 (3), 484-495, 2021 | 39 | 2021 |
| Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells I Vujic, M Sanlorenzo, R Esteve-Puig, M Vujic, A Kwong, A Tsumura, ... Oncotarget 7 (6), 7297, 2016 | 38 | 2016 |
| Phosphoproteomic analyses of NRAS (G12) and NRAS (Q61) mutant melanocytes reveal increased CK2α kinase levels in NRAS (Q61) mutant cells C Posch, M Sanlorenzo, I Vujic, JA Oses-Prieto, BD Cholewa, ST Kim, ... Journal of Investigative Dermatology 136 (10), 2041-2048, 2016 | 37 | 2016 |
